Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 60,574	$ 127,106
Short-term marketable securities	876,295	907,405
Prepaid expenses and other current assets	36,706	29,626
Total current assets	973,575	1,064,137
Long-term marketable securities	490,723	0
Property and equipment, net	46,863	45,589
Operating lease right-of-use asset	25,309	26,048
Other non-current assets	44,621	18,143
Total assets	1,581,091	1,153,917
Current liabilities:
Accounts payable	11,855	9,483
Accrued clinical and other research & development costs	19,956	19,035
Accrued manufacturing costs	16,720	15,462
Other accrued costs and current liabilities	5,986	5,152
Accrued compensation	8,053	21,590
Operating lease liability, current	7,512	7,260
Deferred research funding liability, current	12,500	0
Total current liabilities	82,582	77,982
Operating lease liability, less current portion	43,034	44,981
Total liabilities	125,616	122,963
Commitments and contingencies (Note 6)
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 142,512,856 shares and 138,385,498 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	1,751	1,711
Additional paid-in capital	2,673,033	2,144,811
Accumulated other comprehensive income (loss)	(1,296)	643
Accumulated deficit	(1,218,013)	(1,116,211)
Total stockholders' equity	1,455,475	1,030,954
Total liabilities and stockholders’ equity	$ 1,581,091	$ 1,153,917